Literature DB >> 25610732

The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.

Laura J Vella1, Miles C Andrews1, Anupama Pasam1, Katherine Woods1, Andreas Behren1, Jonathan S Cebon1.   

Abstract

Metastatic melanoma is frequently fatal. Optimal treatment regimens require both rapid and durable disease control, likely best achieved by combining targeted agents with immunotherapeutics. In order to accomplish this, a detailed understanding of the immune consequences of the kinase inhibitors used to treat melanoma is required.

Entities:  

Keywords:  BRAF; MEK; T-lymphocytes; dendritic cells; melanoma

Year:  2014        PMID： 25610732      PMCID： PMC4292757          DOI： 10.4161/21624011.2014.946367

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.

Authors:  Miles C Andrews; Andreas Behren; Fiona Chionh; John Mariadason; Laura J Vella; Hongdo Do; Alexander Dobrovic; Niall Tebbutt; Jonathan Cebon
Journal:  J Clin Oncol       Date:  2013-11-04       Impact factor: 44.544

Review 2.  Tumor adaptation and resistance to RAF inhibitors.

Authors:  Piro Lito; Neal Rosen; David B Solit
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

3.  MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.

Authors:  Laura J Vella; Anupama Pasam; Nektaria Dimopoulos; Miles Andrews; Ashley Knights; Anne-Laure Puaux; Jamila Louahed; Weisan Chen; Katherine Woods; Jonathan S Cebon
Journal:  Cancer Immunol Res       Date:  2014-01-17       Impact factor: 11.151

4.  Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.

Authors:  B Schilling; W Sondermann; F Zhao; K G Griewank; E Livingstone; A Sucker; H Zelba; B Weide; U Trefzer; T Wilhelm; C Loquai; C Berking; J Hassel; K C Kähler; J Utikal; P Al Ghazal; R Gutzmer; S M Goldinger; L Zimmer; A Paschen; U Hillen; D Schadendorf
Journal:  Ann Oncol       Date:  2014-02-06       Impact factor: 32.976

5.  Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma.

Authors:  Paolo A Ascierto; Kim Margolin
Journal:  Cancer       Date:  2014-02-27       Impact factor: 6.860

Review 6.  Immune checkpoint blockade.

Authors:  Jarushka Naidoo; David B Page; Jedd D Wolchok
Journal:  Hematol Oncol Clin North Am       Date:  2014-06       Impact factor: 3.722

7.  Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor.

Authors:  Taha Merghoub; Maria Jure-Kunkel; Jedd D Wolchok; Margaret K Callahan; Gregg Masters; Christine A Pratilas; Charlotte Ariyan; Jessica Katz; Shigehisa Kitano; Valerie Russell; Ruth Ann Gordon; Shachi Vyas; Jianda Yuan; Ashok Gupta; Jon M Wigginton; Neal Rosen
Journal:  Cancer Immunol Res       Date:  2014-01       Impact factor: 11.151

8.  The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.

Authors:  Xiaofeng Jiang; Jun Zhou; Anita Giobbie-Hurder; Jennifer Wargo; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2012-10-24       Impact factor: 12.531

Review 9.  Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.

Authors:  Laura J Vella; Miles C Andrews; Andreas Behren; Jonathan Cebon; Katherine Woods
Journal:  Expert Rev Clin Immunol       Date:  2014-06-17       Impact factor: 4.473

10.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Authors:  Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531
  10 in total
  6 in total

1.  Raising the bar: optimizing combinations of targeted therapy and immunotherapy.

Authors:  Alexandre Reuben; Jacob Austin-Breneman; Jennifer A Wargo; Zachary A Cooper
Journal:  Ann Transl Med       Date:  2015-10

Review 2.  MEK inhibition and immune responses in advanced melanoma.

Authors:  Reinhard Dummer; Egle Ramelyte; Sabrina Schindler; Olaf Thürigen; Mitchell P Levesque; Peter Koelblinger
Journal:  Oncoimmunology       Date:  2017-08-10       Impact factor: 8.110

3.  Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.

Authors:  Elliott J Brea; Claire Y Oh; Eusebio Manchado; Sadna Budhu; Ron S Gejman; George Mo; Patrizia Mondello; James E Han; Casey A Jarvis; David Ulmert; Qing Xiang; Aaron Y Chang; Ralph J Garippa; Taha Merghoub; Jedd D Wolchok; Neal Rosen; Scott W Lowe; David A Scheinberg
Journal:  Cancer Immunol Res       Date:  2016-09-28       Impact factor: 11.151

Review 4.  Targeted Therapies Combined With Immune Checkpoint Therapy.

Authors:  Peter A Prieto; Alexandre Reuben; Zachary A Cooper; Jennifer A Wargo
Journal:  Cancer J       Date:  2016 Mar-Apr       Impact factor: 3.360

Review 5.  Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy.

Authors:  Sangeetha M Reddy; Alexandre Reuben; Jennifer A Wargo
Journal:  Curr Oncol Rep       Date:  2016-07       Impact factor: 5.075

6.  Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.

Authors:  Maria Gonzalez-Cao; Aram Boada; Cristina Teixidó; María Teresa Fernandez-Figueras; Clara Mayo; Francesc Tresserra; Jean Bustamante; Santiago Viteri; Enrique Puertas; Mariacarmela Santarpia; Aldo Riso; Feliciano Barron; Niki Karachaliou; Rafael Rosell
Journal:  Oncotarget       Date:  2016-08-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.